EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis

Hardil Anup Bhatt, Ibrahim Alqassas, Farid Foroutan, Rachel Lu, Mackenzie Dryburgh, Nikhila Butani, Joshua G Lee, Ani Orchanian-Cheff, Darryl P Leong, Anca Prica, Daniel Addison, Lee Mozessohn und 6 weitere

European Heart Journal – Cardio-Oncology · 21.08.2026

DOI: 10.1093/ehjco/aabag005 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Heart Journal – Cardio-Oncology, online erschienen am 21.08.2026. Verfasst von Hardil Anup Bhatt und 17 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ibrutinib increases cardiovascular adverse events, but the comparative cardiovascular safety of second-generation Bruton’s tyrosine kinase inhibitors (BTKi) remains uncertain. We compared cardiovascular adverse events among ibrutinib, acalabrutinib, zanubrutinib, and non-BTKi therapies. Methods and Results We conducted a systematic review and frequentist network meta-analysis of Phase II/III randomised trials of BTKi in adults with haematological malignancies. Outcomes included atrial fibrillation (AF), hypertension, bleeding, heart failure (HF), acute coronary syndrome, stroke, ventricular arrhythmias, and sudden death. Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using non-BTKi therapy as the reference group where possible. Evidence certainty was assessed using GRADE. Twenty-five trials including 12,194 patients were analysed. Compared with non-BTKi therapy, the odds of AF were increased with ibrutinib (OR 4.48, 95% CI 3.48–5.75), acalabrutinib (OR 2.23, 95% CI 1.50–3.32), and zanubrutinib (OR 1.66, 95% CI 1.08–2.56). Bleeding odds were also increased with ibrutinib (OR 3.54, 95% CI 2.45–5.13), acalabrutinib (OR 3.95, 95% CI 2.32–6.73), and zanubrutinib (OR 3.75, 95% CI 2.01–7.00). Hypertension odds were increased with ibrutinib and zanubrutinib, but not acalabrutinib. Only ibrutinib was associated with significantly higher odds of HF and sudden death. No BTKi was associated with significantly higher odds of acute coronary syndrome, stroke, or ventricular arrhythmias than non-BTKi regimens.

Conclusion

Second-generation BTKi were associated with lower risk of AF than ibrutinib, whereas bleeding risk was increased comparably across all BTKi agents. Findings should be interpreted cautiously because several outcomes were rare and imprecisely estimated. (PROSPERO ID#: CRD42023436930).

Zitieren

APA

Bhatt, H. A., Alqassas, I., Foroutan, F., Lu, R., Dryburgh, M., Butani, N., Lee, J. G., Orchanian-Cheff, A., Leong, D. P., Prica, A., Addison, D., Mozessohn, L., Fradley, M., Vijenthira, A., Chakraborty, P., Nanthakumar, K., Thavendiranathan, P., & Abdel-Qadir, H. (2026). Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis. European Heart Journal – Cardio-Oncology. https://doi.org/10.1093/ehjco/aabag005

Vancouver

Bhatt HA, Alqassas I, Foroutan F, Lu R, Dryburgh M, Butani N, et al. Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis. European Heart Journal – Cardio-Oncology. 2026. doi:10.1093/ehjco/aabag005

BibTeX
@article{Bhatt2026,
  author = {Bhatt, Hardil Anup and Alqassas, Ibrahim and Foroutan, Farid and Lu, Rachel and Dryburgh, Mackenzie and Butani, Nikhila and Lee, Joshua G and Orchanian-Cheff, Ani and Leong, Darryl P and Prica, Anca and Addison, Daniel and Mozessohn, Lee and Fradley, Michael and Vijenthira, Abi and Chakraborty, Praloy and Nanthakumar, Kumaraswamy and Thavendiranathan, Paaladinesh and Abdel-Qadir, Husam},
  title = {Cardiovascular Risk of First and Second Generation Bruton’s Tyrosine Kinase Inhibitors: A Systematic Review and Network Meta-Analysis},
  journal = {European Heart Journal – Cardio-Oncology},
  year = {2026},
  doi = {10.1093/ehjco/aabag005}
}
Kostenlos starten →